MedTrace Logo

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2011-03-18

No results posted yet for this study

Summary

This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.

Conditions

  • Venous Retinal Branch Occlusion
  • Central Retinal Vein Occlusion
  • Retinal Vein Occlusion
  • Depression

Interventions

DRUG

ranibizumab (Lucentis)

0.5 mg, administered intravitreally every 4 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Retina Associates of Cleveland, Inc

    lead OTHER

Principal Investigators

  • Lawrence J Singerman, MD · Retina Associates of Cleveland

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01011374 on ClinicalTrials.gov